A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies
Phase 1
- Conditions
- Hematologic Malignancy, Solid MalignancyTherapeutic area: Diseases [C] - Neoplasms [C04]Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2024-512479-11-00
- Lead Sponsor
- CRISPR Therapeutics AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document., Must have received CRISPR CAR cellular therapy.
Exclusion Criteria
There are no specific exclusion criteria.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method